Tumoricidal efficacy of DZ-1 dye conjugated to dihydroartemisinin in patient-derived colorectal liver metastasis tumoroids.

Authors

Farzaneh Vafaeinik, Badrinath Narayanasamy, Sarah Helmueller, Yi Zhang, Alexandra Gangi, Heuiran Lee, Cheryn Song, Robert Figlin, Karine Sargsyan, Yong J Lee

Published in

Molecular therapy. Oncology. Volume 34. Issue 3. Pages 201257. Sep 17, 2026. Epub Jun 04, 2026.

Abstract

Hepatic colorectal metastases, also termed colorectal liver metastases (CRLM), remain a major clinical challenge, despite advances in surgery and chemotherapy. The complexity of CRLM pathology necessitates novel therapeutic approaches, yet current preclinical models often fail to accurately recapitulate the human tumor microenvironment. To overcome these limitations, we utilized patient-derived three-dimensional (3D) CRLM tumoroids to evaluate the efficacy of DZ-1-DHA, a novel conjugate consisting of the heptamethine carbocyanine dye DZ-1 linked to the anti-malarial derivative dihydroartemisinin (DHA). Data from TUNEL and immunoblotting assays revealed that treatment of CRLM tumoroids with DZ-1-DHA led to significant tumor cell death, accompanied by apoptotic signaling. Fluorescence imaging with MitoTracker, 2',7'-dichlorofluorescin diacetate, MitoSOX, and JC-1 showed that DZ-1-DHA accumulates in mitochondria, where it induces generation of cytotoxic reactive oxygen species (ROS) and causes mitochondrial membrane depolarization. Furthermore, data from treatment with deferoxamine or MitoTEMPO indicated that DZ-1-DHA promotes mitochondrial ROS production through a Fenton-like mechanism. These findings demonstrate that DZ-1-DHA triggers apoptosis through mitochondrial stress and apoptotic signaling pathways. Also, DZ-1-DHA represents a promising second-line therapeutic strategy for CRLM. By inducing selective tumor cell death through mitochondrial-targeted apoptosis in a clinically relevant 3D model. This promising approach needs in vivo validation for safety and efficacy.

PMID:
42371539
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.